[1] Lam MG, de Klerk JM, van Rijk PP, et al.  Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases[J]. Anti cancer Agents Med Chem, 2007, 7(4): 381-397.   doi: 10.2174/187152007781058596
[2] Costa L.  Bisphosphonates: reducing the risk of skeletal complications from bone metastasis[J]. Breast, 2007, 16(Suppl 3): S16-S20.
[3] Choong PF.  The molecular basis of skeletal metastases[J]. Clin Orthop Relat Res, 2003, 415(Suppl): S19-S31.
[4] Coleman RE, Seaman JJ.  The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases[J]. Semin Oncol, 2001, 28(2 Suppl 6): 11-16.
[5] Bodei L, Lam M, Chiesa C, et al.  EANM procedure guideline for treatment of refractory metastatic bone pain[J]. Eur J Nucl Med Mol Imaging, 2008, 35(10): 1934-1940.   doi: 10.1007/s00259-008-0841-y
[6] Gkialas I, Iordanidou L, Galanakis I, et al.  The use of radioisotopes for palliation of metastatic bone pain[J]. JBUON, 2008, 13(2): 177-183.
[7] Bauman G, Charette M, Reid R, et al.  Radiopharmaceuticals for the palliation of painful metastasis-a systemic review[J]. Radiother Oncol, 2005, 75(3): 258-270.
[8] TripathiM, SinghalT, ChandrasekharN, etal.  Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases[J]. IndianJCancer, 2006, 43(2): 86-92.
[9] Baczyk M, Czepczyñski R, Milecki P, et al.  89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma[J]. Nucl Med Commun, 2007, 28(4): 245-250.   doi: 10.1097/MNM.0b013e32805b72a0
[10] Liepe K, Kotzerke J.  A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases[J]. Nucl Med Commun, 2007, 28(8): 623-630.   doi: 10.1097/MNM.0b013e32825a6adc
[11] Amato RJ, Hernandez-McClain J, Henary H.  Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer[J]. Am J Clin Oncol, 2008, 31(6): 532-538.   doi: 10.1097/COC.0b013e318172aa92
[12] Pagliaro LC, Delpassand ES, Williams D, et al.  A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases[J]. Cancer, 2003, 97(12): 2988-2994.   doi: 10.1002/cncr.11412
[13] Finlay IG, Mason MD, Shelley M.  Radioisotopes for the palliation of metastatic bone cancer: a systematic review[J]. Lancet Oncol, 2005, 6(6): 392-400.   doi: 10.1016/S1470-2045(05)70206-0
[14] Lewington VJ.  Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(Suppl 1): 38S-47S.
[15] Storto G, Klain M, Paone G, et al.  Combined therapy of 89Sr-and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39(1): 35-41.   doi: 10.1016/j.bone.2005.12.004
[16] Koutsikos J, Leondi A.  Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases[J]. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1392-1393.   doi: 10.1007/s00259-008-0759-4
[17] 梁九根, 蒋宁一, 杜建强, 等.  188Re-羟乙基二膦酸与帕米膦酸二钠联合治疗乳腺癌骨转移的临床价值[J]. 中华肿瘤杂志, 2005, 27(3): 180-182.   doi: 10.3760/j.issn:0253-3766.2005.03.016
[18] Vassiliou V, Bruland O, Janjan N, et al.  Combining systemic bisphosphonates with palliative external beam radiotherapy or bonetargeted radionuclide therapy: interactions and effectiveness[J]. Clin Oncol, 2009, 21(9): 665-667.   doi: 10.1016/j.clon.2009.07.011
[19] Costa L.  Bisphosphonates: reducing the risk of skeletal complications from bone metastasis[J]. Breast, 2007, 16(Suppl 3): S16-S20.
[20] Valachis A, Polyzos NP, Georgoulias V, et al.  Lack of evidence for fracture prevention in early breast cancer bisphos-phonate trials: a meta-analysis[J]. Gynecol Oncol, 2010, 117(1): 139-145.   doi: 10.1016/j.ygyno.2009.12.001